Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,244,224
  • Shares Outstanding, K 257,529
  • Annual Sales, $ 9,869 M
  • Annual Income, $ 3,620 M
  • EBIT $ -270 M
  • EBITDA $ -89 M
  • 60-Month Beta 0.36
  • Price/Sales 12.24
  • Price/Cash Flow 31.94
  • Price/Book 7.73

Options Overview Details

View History
  • Implied Volatility 52.99% ( +3.05%)
  • Historical Volatility 30.05%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 52.99% on 12/18/24
  • IV Low 17.64% on 05/16/24
  • Put/Call Vol Ratio 1.97
  • Today's Volume 9,119
  • Volume Avg (30-Day) 3,636
  • Put/Call OI Ratio 1.22
  • Today's Open Interest 68,358
  • Open Int (30-Day) 58,605

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 3.48
  • Number of Estimates 12
  • High Estimate 4.43
  • Low Estimate 2.98
  • Prior Year 3.57
  • Growth Rate Est. (year over year) -2.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
445.00 +0.56%
on 11/21/24
476.46 -6.08%
on 12/10/24
-19.51 (-4.18%)
since 11/18/24
3-Month
445.00 +0.56%
on 11/21/24
519.88 -13.92%
on 11/08/24
-26.66 (-5.62%)
since 09/18/24
52-Week
391.01 +14.45%
on 04/18/24
519.88 -13.92%
on 11/08/24
+42.85 (+10.59%)
since 12/18/23

Most Recent Stories

More News
2 Unstoppable Stocks to Buy and Hold for the Next Decade

What do Apple (NASDAQ: AAPL) and Vertex Pharmaceuticals (NASDAQ: VRTX) have in common? At first glance, not much. The former is a consumer tech leader while the latter operates in the biotech industry....

AAPL : 248.05 (-2.14%)
VRTX : 447.50 (-4.63%)
4 Big Drug Stocks That May Continue to Outperform in 2025

The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust earnings, and pipeline and regulatory successes. The Zacks Large Cap Pharmaceuticals...

LLY : 764.71 (-1.79%)
VRTX : 447.50 (-4.63%)
GILD : 90.69 (-2.27%)
ABBV : 173.02 (-1.35%)
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025....

CRSP : 41.06 (-8.00%)
IOVA : 7.26 (-7.04%)
VRTX : 447.50 (-4.63%)
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies...

VKTX : 38.28 (-18.03%)
VRTX : 447.50 (-4.63%)
LLY : 764.71 (-1.79%)
PFE : 25.89 (-2.04%)
3 Unstoppable Stocks to Buy Right Now

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter...

AZN : 64.64 (-3.78%)
VRTX : 447.50 (-4.63%)
LLY : 764.71 (-1.79%)
The Ultimate Biotech Stock to Buy With $500 Right Now

Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile.

VRTX : 447.50 (-4.63%)
2 No-Brainer Stocks to Buy Before the End of 2024

I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion. The legendary investor continues to be a net seller of stocks,...

BRK.A : 670,737.69 (-1.96%)
BRK.B : 446.59 (-1.99%)
VRTX : 447.50 (-4.63%)
PFE : 25.89 (-2.04%)
BNTX : 111.61 (-4.92%)
3 No-Brainer Growth Stocks to Buy in December

Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.

NVO : 105.96 (-1.90%)
LLY : 764.71 (-1.79%)
VRTX : 447.50 (-4.63%)
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

Things aren't getting much better for Pfizer (NYSE: PFE) . The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it...

VKTX : 38.28 (-18.03%)
VRTX : 447.50 (-4.63%)
PFE : 25.89 (-2.04%)
Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Despite Vertex Pharmaceuticals’ recent underperformance compared to the Dow Jones, Wall Street analysts remain moderately optimistic about the stock’s prospects.

VRTX : 447.50 (-4.63%)
$DOWI : 42,326.87 (-2.58%)
BIIB : 146.79 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 488.92
2nd Resistance Point 479.99
1st Resistance Point 463.74
Last Price 447.50
1st Support Level 438.56
2nd Support Level 429.63
3rd Support Level 413.38

See More

52-Week High 519.88
Fibonacci 61.8% 470.65
Fibonacci 50% 455.45
Last Price 447.50
Fibonacci 38.2% 440.24
52-Week Low 391.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar